OptumCare Cancer Care at MountainView — Las Vegas, Nevada

OptumCare Cancer Care at MountainView is a clinical research site located in Las Vegas, Nevada, United States 89128.

Crixeo Clinical Trials Trust Score: 33/100 (FAILING). This profile has not yet been claimed by the site owner.

OptumCare Cancer Care at MountainView has participated in 146 clinical trials with 113 currently active.

Therapeutic areas: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma.

Sponsors: National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Las Vegas

Browse all research sites in Nevada · View every site in Las Vegas

Sponsor Feasibility Report

Trust Score: 33/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for OptumCare Cancer Care at MountainView?

OptumCare Cancer Care at MountainView has a Crixeo Trust Score of 33/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has OptumCare Cancer Care at MountainView conducted?

OptumCare Cancer Care at MountainView has 146 clinical trials on record, with 113 currently active. Their work covers Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma.

Is OptumCare Cancer Care at MountainView accredited by Crixeo Clinical Trials?

OptumCare Cancer Care at MountainView has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about OptumCare Cancer Care at MountainView?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.